Insight Molecular Diagnostics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $139.5M
- Price
- $4.32
- % Change (Daily % change from the live per-ticker quote feed.)
- +16.44%
- Volume
- 331.7K
About
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Quick stats
Shares outstanding32.3M
Computed float25.5M
Float / shares78.9%
Cash runway (months)9.8
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001642380
Websitehttps://imdxinc.com
AI Summary
AI-generated1/18
minorbullishoperations update
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
Insight Molecular Diagnostics announced it will host a virtual Key Opinion Leader event on August 17 to discuss its GraftAssure platform and the shift toward in-house testing for transplanted organ rejection.
The event features Dr. Max Jacob Liebo alongside company executives, focusing on the GraftAssureDx kit which is currently under FDA review for kidney transplant rejection monitoring.
Management aims to transition testing from centralized send-out models to local hospital labs to improve result turnaround times and patient care.